NCT05403476 - A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

October 5, 2024

Study Completion Date

October 23, 2024

Conditions

Male Idiopathic Infertility

Interventions

DRUG

FE 999049

FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.

DRUG

Placebo

Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.

Trial Locations (22)

10065

Ferring Investigational Site, New York

19713

Ferring Investigational Site, Newark

27607

Ferring Investigational Site, Raleigh

60612

Ferring Investigational Site, Chicago

66160

Ferring Investigational Site, Kansas City

73104

Ferring Investigational Site, Oklahoma City

76022

Ferring Investigational Site, Bedford

77598

Ferring investigational site, Webster

80112

Ferring Investigational Site, Centennial

84108

Ferring Investigational Site, Salt Lake City

85284

Ferring Investigational Site, Tempe

95124

Ferring Investigational Site, San Jose

98195

Ferring Investigational Site, Seattle

Unknown

Ferring Investigational Site, Brussels

Ferring Investigational Site, Copenhagen

Ferring Investigational Site, Halle

Ferring Investigational Site, Münster

Ferring Investigational Site, Modena

Ferring Investigational Site, Rome

Ferring Investigational Site, Valencia

Ferring Investigational Site, Malmo

Ferring Investigational Site, Stockholm